engleski

PD-L1 Testing in University Hospital Centre Osijek

Lung cancer remains leading course of cancer deaths worldwide, with poor prognosis. Hitherto, treatment therapies for non-small cell lung cancer (NSCLC) included surgery, chemotherapy, radiation and targeted therapy. Over recent years, following development of personalized medicine and progression in cancer immunology research, programmed death-ligand 1 (PD-L1) has emerged as a significant cancer biomarker and immunotherapy target. Department for Pathology and Forensic Medicine of University Hospital Centre Osijek (KBCO) introduced PD-L1 expression testing in June, 2018, in addition to evaluation of EGFR and ALK. Test is performed using SP263 antibody clone on Ventana BenchMark Ultra platform, both on tissue and cell-block samples. Positivity is scored based on partial or complete membrane staining (at any intensity). Thus far, PD-L1 expression has been analyzed in 62 patients ; 45 male and 17 female (including patients from KBCO, as well as those that were sent for consultation). Majority of tests were done on tissue samples (74%). Expression of PD- L1 <1% was estimated in 37% of patients, and score of >50% was estimated in 24%. Furthermore, when applicable, EGFR and ALK tests were also performed. Test for EGFR mutation was done on 58 patients, with positivity in 5% of cases. For ALK immunohistochemistry test was applicable for 53 patients and scored positive in 2%. To date, immunotherapy showed encouraging results in treatment of patients with NSCLC, therefore analyzing PD-L1 status has become integrated in pathologist work and clinical approach.

PD-L1, immunotherapy

nije evidentirano